Acumen Pharmaceuticals (ABOS) News Today $1.49 +0.09 (+6.43%) Closing price 04:00 PM EasternExtended Trading$1.48 0.00 (-0.34%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABOS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Acumen Pharmaceuticals to Present Findings on Sabirnetug at ... - NasdaqJuly 12 at 10:28 AM | nasdaq.comAcumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025July 10, 2025 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Trading Up 4.3% - Still a Buy?July 9, 2025 | marketbeat.comAcumen Pharmaceuticals Inc News (ABOS) - Investing.comJuly 2, 2025 | investing.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Increase in Short InterestJune 17, 2025 | marketbeat.comCitigroup Begins Coverage on Acumen Pharmaceuticals (NASDAQ:ABOS)June 17, 2025 | marketbeat.comBrokers Issue Forecasts for ABOS FY2026 EarningsJune 11, 2025 | marketbeat.comMillennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)June 2, 2025 | marketbeat.comFY2025 EPS Estimates for ABOS Reduced by Cantor FitzgeraldMay 21, 2025 | marketbeat.comAcumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug developmentMay 15, 2025 | seekingalpha.comAcumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comAcumen Pharmaceuticals (NASDAQ:ABOS) Issues Earnings Results, Beats Estimates By $0.46 EPSMay 15, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comAcumen Pharmaceuticals Inc (ABOS) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ...May 14, 2025 | finance.yahoo.com3ABOS : A Preview Of Acumen Pharmaceuticals's EarningsMay 12, 2025 | benzinga.comAcumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.comAcumen Pharmaceuticals to Participate in the Bank of America Healthcare ConferenceMay 7, 2025 | globenewswire.comAcumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025May 6, 2025 | globenewswire.comJPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 28, 2025 | marketbeat.comRock Springs Capital Management LP Trims Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 23, 2025 | marketbeat.comFranklin Resources Inc. Has $5.63 Million Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)April 13, 2025 | marketbeat.comAcumen presented results from pTau217 assay in Phase 2 ALTITUDE-AD trialApril 3, 2025 | markets.businessinsider.comAcumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual MeetingApril 2, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ABOS FY2029 Earnings?March 31, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | seekingalpha.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comUBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00March 29, 2025 | marketbeat.comAcumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $11.00 at HC WainwrightMarch 29, 2025 | marketbeat.comQ4 2024 Acumen Pharmaceuticals Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comAcumen price target lowered to $11 from $15 at H.C. WainwrightMarch 29, 2025 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)March 29, 2025 | markets.businessinsider.comAcumen Pharmaceuticals’ Earnings Call: Progress Amid ChallengesMarch 28, 2025 | tipranks.comAcumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings ResultsMarch 28, 2025 | marketbeat.comAcumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timelineMarch 27, 2025 | msn.comAcumen completes enrollment of ALTITUDE-AD Phase 2 trialMarch 27, 2025 | markets.businessinsider.com1ABOS : Preview: Acumen Pharmaceuticals's EarningsMarch 27, 2025 | benzinga.comAcumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s DiseaseMarch 26, 2025 | markets.businessinsider.comAcumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 StudyMarch 21, 2025 | nasdaq.comAcumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025March 20, 2025 | globenewswire.comAcumen Pharmaceuticals at Stifel CNS Days: Alzheimer’s Drug ProgressMarch 20, 2025 | investing.comAcumen announces results from Phase 1 study of sabirnetug in volunteersMarch 19, 2025 | markets.businessinsider.comAcumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy VolunteersMarch 19, 2025 | markets.businessinsider.comAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’sMarch 18, 2025 | finance.yahoo.comAcumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer'sMarch 18, 2025 | globenewswire.comAcumen Pharmaceuticals (ABOS) Projected to Post Earnings on TuesdayMarch 18, 2025 | marketbeat.comAcumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual MeetingMarch 12, 2025 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Down 4% - Here's What HappenedMarch 11, 2025 | marketbeat.comAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesMarch 10, 2025 | globenewswire.comABOS stock touches 52-week low at $1.31 amid market challengesFebruary 11, 2025 | msn.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateFebruary 2, 2025 | marketbeat.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.641.01▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼42▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RCKT News Today FHTX News Today ADCT News Today AVTE News Today TSVT News Today CRVS News Today ANNX News Today TRDA News Today CMPS News Today ALLO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored“The Best Gold Investment You’ve Never Heard Of”Gold may be surging past $3,500 — but one rare class of stocks is leaving bullion in the dust. Gold royalti...Golden Portfolio | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
